Your Followed Topics

69.1K est. views
health1d ago

WHO issues guidance on GLP-1 drugs for obesity, calls them a "scientific breakthrough" and "new chapter"

https://www.cbsnews.com/news/who-guidance-glp-1-drugs-obesity/https://www.euronews.com/health/2025/12/01/weight-loss-drugs-and-healthy-lifestyles-recommended-to-treat-obesity-who-sayshttps://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity
Cbsnews.com and 6 more
WHO issues guidance on GLP-1 drugs for obesity, calls them a "scientific breakthrough" and "new chapter" Open in Cbsnews.com
Highlights
  • The World Health Organization now recommends GLP-1 drugs for adults with obesity as part long-term treatment, alongside behavioral therapy and monitoring.
  • The guidance marks a shift from viewing obesity as a lifestyle issue to a chronic disease needing ongoing, comprehensive care.
  • Global access and affordability are prioritized, with urgent actions urged on manufacturing, pricing, and health system readiness.

Virality Score Timeline

Vote 18
0

References

WHO advises weight loss drugs and healthy lifestyles to treat obesity

WHO advises weight loss drugs and healthy lifestyles to treat obesity

WHO issues global guideline on the use of GLP-1 medicines in treating obesity

WHO issues global guideline on the use of GLP-1 medicines in treating obesity

WHO recommends GLP-1 drugs for obesity

WHO recommends GLP-1 drugs for obesity

WHO says weight loss drugs are ‘new chapter’ in fight against obesity

WHO says weight loss drugs are ‘new chapter’ in fight against obesity

WHO Sets GLP-1 Weight-Loss Drug Guidelines

WHO Sets GLP-1 Weight-Loss Drug Guidelines

WHO backs use of GLP-1 therapies for obesity, warns access will remain limited

WHO backs use of GLP-1 therapies for obesity, warns access will remain limited

Related Topics

0 Comments

Be the first to comment

Add your thoughts and get the conversation going.

Top 731 Internet News Today

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Advertisement

Advertisement